| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8647203 | Multiple Sclerosis and Related Disorders | 2018 | 6 Pages |
Abstract
: A small but important number of issues have been consistently identified by the PBAC in relation to submissions for reimbursement of MS drugs. Drug developers and clinical trial investigators who are aware of these issues will be able to anticipate data requirements for reimbursement decision-making and thus potentially improve the evidence submitted for listing of MS drugs in Australia.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Yen Hoang Le Phan, Richard De Abreu Lourenco, Marion Haas, Naomi van der Linden,